Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

MLL Rearrangement: early-phase trial registry

1 of 1 indexed MLL Rearrangement trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

MLL Rearrangement: 1 US clinical trial tracked, 1 recruiting.

MLL Rearrangement is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Kura Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition mll-rearrangement

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

MLL Rearrangement (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near MLL Rearrangement

MLL Rearrangement lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for MLL Rearrangement on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. MLL Rearrangement is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Kura Oncology 1 trials

Named interventions

Most-linked intervention names on MLL Rearrangement records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ziftomenib Drug
1 trials
Gilteritinib Drug
1 trials
Idarubicin Drug
1 trials
Cytarabine Drug
1 trials
Fludarabine Drug
1 trials

US sites by state

Facility locations filed on MLL Rearrangement trials. A trial with sites in several states counts in each.

New York 1 trials
New Jersey 1 trials
Nebraska 1 trials
Michigan 1 trials
Massachusetts 1 trials
Kansas 1 trials
Illinois 1 trials
Iowa 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this MLL Rearrangement page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 MLL Rearrangement trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Kura Oncology sponsors the most MLL Rearrangement trials on record, review their full trial history before evaluating a specific study. See Kura Oncology's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MLL Rearrangement condition card totals 1 registered trials; most-linked intervention Ziftomenib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.